Tolerability of Fosamprenavir/ Ritonavir Associated With Zidovudine-Lamivudine Used as Postexposure Prophylaxis for HIV Infection

摘要

To the Editor:The French 2003 guidelines for management of postexposure prophylaxis (PEP) for human immunodeficiency virus (HIV) infection1 recommend the use of a 4-week course of triple antiretroviral therapy with 2 nucleoside analogues and 1 protease inhibitor in cases of both occupational and nonoccupational exposures.To our knowledge, the combination of zidovudine-lamivudine (Combi-vir) and fosamprenavir/ritonavir twice aday has not been tested for this indication. We decided to test this association; this choice was based on multiple arguments: The need to use a protease inhibitor as recommended in France with a limited burden of pills to improve patient adherence and with a not too expensive cost.